


Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the application:

5

1. (Original) A compound structurally represented by Formula I



(I)

- 10 or pharmaceutically acceptable salts thereof wherein:

G^1 is $-\text{CH}_2-$, or $-\text{CH}_2\text{-CH}_2-$,

G^2 is $-\text{CH}_2-$, or $-\text{C(O)}-$,

or G^1 and G^2 taken together combine to form $-\text{CH=CH}-$ or $-\text{CH}_2\text{-CH=CH}-$,

- 15 Y is

$-\text{OCH}_2\text{CH}_2\text{N-piperidinyl}$,

$-\text{OCH}_2\text{CH}_2\text{CH}_2\text{N-piperidinyl}$,

$-\text{OCH}_2\text{CH}_2\text{N-pyrrolidinyl}$,

$-\text{OCH}_2\text{CH}_2\text{CH}_2\text{N-pyrrolidinyl}$,


- 20 X is H, $-\text{COR}^3$, $-\text{CH}_2\text{R}^4$, $-\text{SO}_2\text{R}^5$,

R^3 is

$-(\text{C}_1\text{-C}_8)$ alkyl, optionally substituted with 1 to 3 halogens,

$-(\text{C}_3\text{-C}_8)$ cycloalkyl, optionally substituted with 1 to 3 halogens,

$-\text{O}(\text{C}_1\text{-C}_8)$ alkyl, optionally substituted with 1 to 3 halogens,



, wherein R⁶ is -(C₁-C₆) alkyl, or -COO-(C₁-C₆) alkyl,

-Furanyl,

-Thienyl,

-NH-phenyl,

5 -NH-(C₁-C₄)alkyl-phenyl,

-NH-(C₁-C₈) alkyl, optionally substituted with 1 to 4 halogens,

-NH-(C₃-C₈) cycloalkyl, optionally substituted once or twice with halogens,

-CH₂-Pyridinyl,

-CH₂N (C₁-C₆) alkyl (C₁-C₆) alkyl,

10 -CH₂N-phenyl,

R⁴ is

-(C₁-C₈) alkyl, optionally substituted with 1 to 4 halogens,

-(C₃-C₈) cycloalkyl,

-(C₁-C₈) alkyl-NH₂,

15 -(C₁-C₄) alkyl -phenyl,

-CH₂N-phenyl,

-phenyl-O-(C₁-C₄) alkyl -phenyl,

-(C₁-C₄) alkyl-O-(C₁-C₄) alkyl-phenyl,

-CH₂NCO₂-(C₁-C₆) alkyl,


20 -Phenyl,

-Thienyl,

-Furanyl,

-Imidazolyl,

-Naphthyl,



, wherein R^6 is $-(C_1-C_6)$ alkyl, or $-COO-(C_1-C_6)$ alkyl,

-Biphenyl, and

R^5 is

-Phenyl,







5






$-(C_1-C_4)$ alkyl,







$-(C_1-C_4)$ alkyl-phenyl.







2. (Original) The compound of claim 1, wherein R^1 and R^2 cyclize to form a 5-membered ring.
3. (Original) The compound of claim 1, wherein R^1 and R^2 cyclize to form a 6-membered ring.
- 10 4. (Original) The compound of claim 2 wherein Y is in the 5 position.
5. (Original) The compound of claim 3 wherein Y is in the 6 position.
6. (Original) The compound of claim 4 wherein X is CO.
7. (Original) The compound of claim 1, selected from the group consisting of:






Example Number	Structure
1	
2	
3	






4	
5	
6	
7	
8	
9	






10	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)CCN(C3)CC4CCCCC4</chem>
11	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)CCN(C3)S(=O)(=O)c4ccccc4</chem>
12	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)CCN(C3)C(=O)OC(C)(C)C</chem>
13	 <chem>ClC1CCCN1CCCOc2ccc3c(c2)CCN3</chem>
14	 <chem>CCN1CCc2ccc(OCCCN3CCCCC3)cc21</chem>





15	
16	
17	
18	
19	
20	






21	 <chem>ClCCN1CCCCC1Oc2cc3c(cc2)ccn3Cl</chem>
22	 <chem>ClCCCN1CCCCC1Oc2cc3c(cc2)ccn3CCl</chem>
23	 <chem>ClCCCN1CCCCC1Oc2cc3c(cc2)ccn3Cc4ccccc4</chem>
24	 <chem>ClCCCN1CCCCC1Oc2cc3c(cc2)ccn3CC4=CN=CN4</chem>
25	 <chem>ClCCCN1CCCCC1Oc2cc3c(cc2)ccn3Cc4ccsc4</chem>
26	 <chem>ClCCCN1CCCCC1Oc2cc3c(cc2)ccn3Cc4ccsc4</chem>






27	
28	
29	
30	
31	






32	 <chem>CCCCCN1Cc2cc(OCCCN3CCCCC3)ccc21</chem>
33	 <chem>CCOc1ccccc1CCN1Cc2cc(OCCCN3CCCCC3)ccc21</chem>
34	 <chem>CC(c1ccccc1)CN1Cc2cc(OCCCN3CCCCC3)ccc21</chem>
35	 <chem>CC(C)(c1ccccc1)CCN1Cc2cc(OCCCN3CCCCC3)ccc21</chem>
36	 <chem>CCN1Cc2cc(OCCCN3CCCCC3)ccc21</chem>





37	 <chem>C1CCN(C1)CCCCOc2ccc3c(c2)CNC(C3)CCCCc4ccccc4</chem>
38	 <chem>CC(C)(C)OC(=O)NCCCCN1Cc2ccc(OC3CCN(C3)CCC)cc2</chem>
39	 <chem>CC(C)N1Cc2ccc(OC3CCN(C3)CCC)cc2</chem>
40	 <chem>O=S(=O)(c1ccccc1)N1Cc2ccc(OC3CCN(C3)CCC)cc2</chem>
41	 <chem>OS(=O)(=O)N1Cc2ccc(OC3CCN(C3)CCC)cc2</chem>

42	 <chem>CCCCS(=O)(=O)N1CCc2cc(OC3CCCN3)ccc21</chem>
43	 <chem>c1ccccc1CS(=O)(=O)N1CCc2cc(OC3CCCN3)ccc21</chem>
44	 <chem>c1ccccc1CN(C(=O)N1CCc2cc(OC3CCCN3)ccc21)C(=O)O</chem>
45	 <chem>CC(C)N(C(=O)N1CCc2cc(OC3CCCN3)ccc21)C(=O)O</chem>

46	 <chem>O=C(Nc1ccccc1)c2c(c1ccc(OCCCN3CCCCC3)cc1)C=C2</chem>
47	 <chem>O=C(NCc1ccccc1)c2c(c1ccc(OCCCN3CCCCC3)cc1)C=C2</chem>
48	 <chem>O=C(NCCCc1ccccc1)c2c(c1ccc(OCCCN3CCCCC3)cc1)C=C2</chem>
49	 <chem>O=C(CCCCc1ccccc1)c2c(c1ccc(OCCCN3CCCCC3)cc1)C=C2</chem>
50	 <chem>O=C(Cc1ccccc1)c2c(c1ccc(OCCCN3CCCCC3)cc1)C=C2</chem>

51	<div>Chiral</div> 
52	<div>Chiral</div> 
53	
54	
55	

56	
57	Chiral 
58	
59	Chiral 
60	Chiral 

61	
62	
63	
64	

or a pharmaceutically acceptable salt or solvate thereof.

8. (Currently amended) A pharmaceutical composition which comprises a compound
 5 of ~~any of claims 1-7~~ 1 or 7 and a pharmaceutically acceptable carrier.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Currently amended) A method for treatment or prevention of obesity which
 10 comprises administering to a subject in need of such treatment or prevention an
 effective amount of a compound of ~~any of Claims 1-7~~ 1 or 7.

13. (Original) The method of Claim 12 wherein the antagonist is a pharmaceutical composition of claim 8.
14. (Currently amended) A method for treatment or prevention of a cognitive disorder ~~or disease in which inhibition of the histamine H3 receptor has a beneficial effect~~ which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of claims 1-7~~ 1 or 7.
- 5
15. (New) The method of Claim 15 wherein the antagonist is a pharmaceutical composition of claim 8.